Drug Trial Radar · NCT01257737
To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)
Last checked: Nov 20, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
88
Actual
Start
Oct 4, 2010
Primary completion
Feb 16, 2017
Study completion Feb 16, 2017
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Dec 10, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an open-label, long-term safety study of HPN-100 (RAVICTI; glycerol phenylbutyrate) in participants with a urea cycle disorder (UCD) who completed the safety extensions of HPN-100-005 (NCT00947544; HPN-100-005SE), HPN-100-006 (NCT00947297; HPN-100-007), or HPN-100-012 (NCT01347073; HPN-100-012SE). The initial studies were 1- to 2-week crossover studies, and their associated safety extensions were 12-month, open-label studies. All participants who completed the initial studies were eligible to enroll in the associated safety extension studies, and new participants were also permitted to enroll directly into the safety extension studies.
Conditions
- Urea Cycle Disorders
Interventions
HPN-100Drug
Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine \[PAGN\] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With at Least One Adverse EventTime frame: From the time of informed consent until 7 days after the last dose of study drug, up to 66 months
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
UCLA Pediatrics/Genetics
Los Angeles, California
Stanford University School of Medicine
Palo Alto, California
Denver Children's Hospital
Aurora, Colorado
Children's National Medical Center
Washington D.C., District of Columbia
Maine Medical Center
Portland, Maine
University of Minnesota Medical Center
Minneapolis, Minnesota
Mount Sinai School of Medicine
New York, New York
University Hospitals Case Medical Center
Cleveland, Ohio
Nationwide Children's Hospital
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
Children's Hospital of Pittsburg of UPMC
Pittsburgh, Pennsylvania
Baylor College of Medicine
Houston, Texas
University of Utah
Salt Lake City, Utah
Seattle Children's Hospital
Seattle, Washington
Children's Hospital of Wisconsin
Milwaukee, Wisconsin
The Hospital for Sick Children
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.